Navigation Links
PTC Therapeutics Announces Achievement of Major Milestone in Wellcome Trust BMI1 Collaboration
Date:7/11/2012

SOUTH PLAINFIELD, N.J., July 11, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that it has selected an experimental drug candidate to advance in its BMI1 program for aggressive and drug-resistant tumors. The milestone triggers drawdown of the next $2.3 million installment of its Seeding Drug Discovery Award from the Wellcome Trust.

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

The candidate, PTC596, is a first-in-class, oral, potent and selective inhibitor of BMI1 protein expression. BMI1 is a protein that plays a central role in the survival and maintenance of tumor stem cells. Tumor stem cells are resistant to current chemotherapy treatments and contribute to tumor recurrence. Elevated levels of BMI1 are associated with more aggressive tumors and a poor prognosis in a wide variety of cancers including glioblastoma. Reducing levels of BMI1 therefore represents a promising new therapeutic strategy to treat drug-resistant cancers.

PTC596 acts by altering the post-translational modification of the BMI1 protein, resulting in reduced levels of BMI1 protein and subsequently reduced action of epigenetic complexes dependent on BMI1. Inhibition of these important complexes leads to the reduced survival and proliferation of tumor stem cells. PTC596 has the potential to be used as a monotherapy or in combination with current standards of care in multiple tumor types.

PTC received a $5.4 million Seeding Drug Discovery Award from the Wellcome Trust in June 2010. In March 2011, PTC announced that it had achieved its first milestone, the identification of a chemical series that penetrate the blood-brain barrier in animal models and reduce levels of BMI1.

"We are proud to reach this important milestone," stated Stuart Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics. "By targeting one of the underlying causes of tumor recurrence and drug resistance, PTC's oral BMI1 inhibitor has the potential to address aggressive or treatment-resistant tumors in patients. This significant milestone further demonstrates the effectiveness of PTC's technologies in identifying compounds against challenging but important therapeutic targets. Discovering compounds like PTC596 is consistent with our mission to develop novel treatments for serious and life-threatening diseases with high unmet need."

About Wellcome Trust

The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust's breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests. www.wellcome.ac.uk

About PTC Therapeutics, Inc.

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and that have served as the basis for collaborations with leading biopharmaceutical companies such as AstraZeneca, Celgene, Genzyme, Merck, Pfizer and Roche. For more information, visit the company's website at www.ptcbio.com.

 


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
2. NIPTE Will Participate in NIHs Therapeutics for Rare and Neglected Diseases (TRND) Program
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent
5. Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
6. The New Generation of Antibody Therapeutics: Current Status and Future Prospects - Overview
7. Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
8. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
9. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
10. Faruqi & Faruqi, LLP is Investigating Pain Therapeutics Inc. on Behalf of its Shareholders (PTIE)
11. Sirnaomics Received NIH SBIR Grant for Developing Its Scarless Wound Healing siRNA Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology:
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
Breaking Medicine News(10 mins):